Feces

DEINOVE to present data on DNV3837 at the ESCMID/ASM conference in Dublin

Retrieved on: 
Mercredi, octobre 5, 2022
CDC, Constipation, Epithelium, White Blood Cells, Infection, Clostridioides difficile (bacteria), Feces, QIDP, Virulence, Toxic megacolon, Diarrhea, CDI, Patient, Clostridioides difficile infection, Perforated ulcer, Collection, GI, Subclinical infection, Centers for Disease Control and Prevention, ISIN, Center, Vomiting, Company, Physiology, Gram-positive bacteria, Blood, Disease, Incidence, Bacteria, Recurrence, Vancomycin, Ileus, Intubation, Heart, Global health, FDA, Pharmaceutical industry, Vaccine, Dietary supplement, Antibiotics, Clostridioides

Preclinical and clinical data show that the prodrug DNV3837 is rapidly converted to DNV3681 in vivo and that the active drug mostly concentrates in the GI tract.

Key Points: 
  • Preclinical and clinical data show that the prodrug DNV3837 is rapidly converted to DNV3681 in vivo and that the active drug mostly concentrates in the GI tract.
  • The diarrhea episodes improved after 6 days of treatment and came back to normal 10 days after treatment after a transient constipation period.
  • Georges Gaudriault, Chief Scientific Officer of DEINOVE who attended the ESCMID/ASM conference in Dublin specifies: The use of DNV3837 is a potential paradigm shift.
  • Located at the heart of the Euromedecine park in Montpellier, DEINOVE has been listed on EURONEXT GROWTH (ALDEI - code ISIN FR0010879056) since 2010.

Global Media, Sera and Reagent Market Research and Forecast 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, septembre 23, 2022
Health, Pharmaceutical, Feces, Technology, Growth, News, Molecular biology, AI Global Media, D, Sera, MP, CAGR, Fine chemical, Marketing

The "Global Media, Sera and Reagent Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Media, Sera and Reagent Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global media, sera, and reagents market is growing at a considerable CAGR of 5.8% during the forecast period.
  • Rising R&D towards the market is one of the prime factors affecting and driving the market.
  • New product launches in the market are likely to drive the growth of the global media, sera, and reagents market.

Colorectal Cancer Epidemiology Analysis and Forecast 2022 - ResearchAndMarkets.com

Retrieved on: 
Mercredi, septembre 7, 2022
Health, Oncology, Lung cancer, Fatigue, II, Cancer, Diarrhea, Sex, American Joint Committee on Cancer, Anemia, Disease, Colon, Recurrence, Colorectal cancer, Feces, AJCC, Risk, Blood, Rectum, Diagnosis, Bloating, Large intestine, Abdominal pain, American Cancer Society, Constipation, Weight loss, Polyp, Therapy, Population, III, World, World Health Organization, CRC, Profile, Epidemiology, Dietary supplement, Medical imaging, Pharmaceutical industry

The "Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • Colorectal cancer (CRC) (ICD-10 = C18-C20), also referred as bowel cancer, is the cancer of the colon, rectum, or rectosigmoid junction.
  • CRC is the second most lethal cancer after lung cancer, and the third most diagnosed malignant tumor worldwide (World Health Organization, 2022).
  • The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC.

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

Retrieved on: 
Mardi, septembre 6, 2022
U.S. Department of Commerce Office of Security, Spleen, Public health, Human, Food, RNA, Safety, National Institute, NYSE, Program, Research, Government, Liver, Sierra Leone, Infection, Vaccine, Disease, Solution, Feces, Risk, SVP, LinkedIn, CEPI, National Institute of Allergy and Infectious Diseases, VSV, NIH, SEC, RATS, EBS, National Institutes of Health, Coalition for Epidemic Preparedness Innovations, National, Emergent BioSolutions, Lassa fever, GLOBE, Office of Inspector General, U.S. Department of Health and Human Services, Emergent, Instagram, Lassa mammarenavirus, Yale University, Therapy, Emergency, Twitter, NIAID, Nursing, Knowledge, Marketing, Licensure, Open access, Private Securities Litigation Reform Act, Urine, Life, Pharmaceutical industry

GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection.

Key Points: 
  • GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection.
  • This Phase 1 study, a randomized, placebo-controlled, dose-escalation study, will evaluate the safety and immunogenicity of Emergents rVSV-vectored Lassa virus vaccine in approximately 36 healthy adults at the Navrongo Health Research Centre and Kintampo Health Research Centre in Ghana.
  • Lassa virusa single-stranded RNA virus belonging to the family Arenaviridaecan cause the acute viral hemorrhagic illness known as Lassa fever.
  • In 2018, Emergent acquired development rights to the Profectus Lassa vaccine candidate now named EBS-LASV.

Number of Victims in the Wendy's E. Coli Outbreak Grows to 97 in 6 States: Ron Simon & Associates Files First Michigan Lawsuit and Anticipates New Cases Will be Identified Over the Labor day Weekend

Retrieved on: 
Vendredi, septembre 2, 2022
Escherichia coli, Wendy's, Office of Inspector General, U.S. Department of Health and Human Services, Public health, Legislation, STEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NBC, H7, Food Safety and Inspection Service, Feces, HUS, Food, Dysentery, CNN, Multimedia, Double, Abdominal pain, U.S. Department of Agriculture Cotton Annex, FOX, Center, Television, FDA, Centers for Disease Control and Prevention timeline, Dave, Microdeletion syndrome, Food safety, ABC, Poisoning, Bacteria, CDC, Lettuce, Nausea, CBS, Poultry

These numbers are expected to increase significantly over the next few weeks.

Key Points: 
  • These numbers are expected to increase significantly over the next few weeks.
  • E. coli is a bacteria that is usually transmitted through human feces, and early indications point to Romaine lettuce on Wendy's sandwiches.
  • Over the last 20 years, Ron Simon and his colleagues have prosecuted thousands of food poisoning cases for victims across the United States.
  • He regularly publishes articles about food safety and litigation at www.foodpoisoningnews.com which are read by viewers in over 180 countries.

Colorectal Cancer Market Report 2022-2028: Increasing Prevalence of Colorectal Cancer & Benefits Offered by Generic Drugs to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Jeudi, août 18, 2022
Pharmaceutical, Health, Oncology, Death, Modality, CRC, 40, Growth, India Brand Equity Foundation, Feces, Prevalence, Medical tourism, Insurance, Blood, Patient, CEA, COVID-19, Colorectal cancer, Vaccine, Colonoscopy, CAGR, Pressure, Immunohistochemistry, FOBT, Australian Institute of Health and Welfare, Pharmaceutical industry, Medical imaging

The global colorectal cancer market is expected to grow from US$ 18,619.3 million in 2022 to US$ 24,078.5 million by 2028.

Key Points: 
  • The global colorectal cancer market is expected to grow from US$ 18,619.3 million in 2022 to US$ 24,078.5 million by 2028.
  • Factors such as the increasing prevalence of colorectal cancer, product launches, and benefits offered by generic drugs are driving the growth of the global colorectal cancer market.
  • However, pricing pressure on drug manufacturers is hampering the global colorectal cancer market growth.
  • The increasing medical tourism and the growing pharmaceutical industry in emerging countries are expected to boost the global colorectal cancer market growth.

ASPCA Assists Union County Sheriff's Office in Rescuing More than 50 Animals from Florida Neglect Case

Retrieved on: 
Jeudi, août 18, 2022
United States Secretary of Labor, Union County Sheriff's Office, Cat, Health, FUR, ASPCA, American Society for the Prevention of Cruelty to Animals, Hoarding, Dog, Society, Urine, Human, Instagram, Twitter, Eighth, SPCA, Feces, Emergency shelter, Ammonia, Animal, Facebook, Animal

LAKE BUTLER, Fla., Aug. 18, 2022 /PRNewswire/ -- At the request of the Union County Sheriff's Office and Union County Animal Control, the ASPCA® (American Society for the Prevention of Cruelty to Animals®) is assisting with the rescue of more than 50 cats and dogs from a property in Lake Butler, Fla. When investigators arrived on the property, they discovered the animals, including newborn kittens, living in filthy conditions amongst their own feces and urine and exposed to elevated levels of ammonia. Some of the animals were underweight and appeared to be suffering from untreated medical conditions.

Key Points: 
  • The ASPCA is also assisting with operational planning, evidence collection, legal assistance, forensics exams, medical care, and behavioral treatment and enrichment for the animals.
  • The animals removed from the property by the ASPCA are being relocated to their Cruelty Recovery Center.
  • We always take animal cruelty seriously and it will not be tolerated in our county," said Union County Sheriff Brad Whitehead.
  • Animal cruelty charges are pending based on evidence collected by the Union County Sheriff's Office with the assistance of ASPCA experts in support of the investigation.

Vivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine Therapy

Retrieved on: 
Mardi, août 16, 2022
FDA, Sarcoma, Forward-looking statement, Name, GLOBE, Neoplasm, Technology, Private Securities Litigation Reform Act, Half-life, Washington State University Reactor, Sale, Tissue, Urine, Hydrogel, Method, Brachytherapy, University, Marketing, Engineering, Company, Gel, Structured Product Labeling, Radiation, Safety, FDA Center for Devices and Radiological Health, Feces, OTCQB, Confusion, Food and Drug Administration, Human, Animal, Vivos, Veterinary medicine, Food, Temperature, Horse, Pharmaceutical industry, Medical imaging

Richland WA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it just certified the New England Equine Practice in Patterson, NY to administer Precision Radionuclide IsoPet therapy for treating solid tumors in horses.

Key Points: 
  • Richland WA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it just certified the New England Equine Practice in Patterson, NY to administer Precision Radionuclide IsoPet therapy for treating solid tumors in horses.
  • Dr. Korenko stated, We are in active discussions related to opening additional equine clinics and are excited about offering Isopet as a game changing treatment option for treating solid tumors in horses.
  • Vivos Inc. has developed an Yttrium-90 based injectable Precision Radionuclide Therapy brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).
  • Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet to University animal hospitals and private veterinary clinics.

More than 400 beagles are removed from laboratory breeding facility in Virginia by the Humane Society of the United States and partners

Retrieved on: 
Vendredi, juillet 22, 2022
People, MSPCA, Feces, TLC, Food, Animal Welfare Act, Injury, Laboratory, Department of Justice (Ireland), Twitter, CEO, HSUS, Humane Society of the United States, Brothers in Unity, Animal, Humanity World International, Pet, Multimedia, Organization, Humane society, Department, Justice, Dog, Hunting, Envigo

WASHINGTON, July 22, 2022 /PRNewswire/ -- Yesterday, the Humane Society of the United States and several shelter and rescue partners embarked on a historic operation and removed the first 432 out of approximately 4,000 beagles at Envigo RMS LLC's facility in Cumberland, Virginia, which bred dogs to be sold to laboratories for animal experimentation.

Key Points: 
  • Homeward Trails, Priceless Pets, Helen Woodward Animal Center and Kindness Ranch Animal Sanctuary picked up groups of dogs removed from the facility yesterday.
  • The Humane Society of the United States brought 201 beagles to its care and rehabilitation center where they will receive care and TLC until they are transported to MSPCA, Wisconsin Humane and Dakin Humane later in the week.
  • People interested in adopting one of the beagles should view the HSUS' list of partners that are accepting the beagles into their adoption program here.
  • We fight all forms of animal cruelty to achieve the vision behind our name: a humane society.

Published studies find low documented adherence to guideline-based care for female urinary incontinence

Retrieved on: 
Vendredi, juillet 22, 2022
Diagnosis, Obstetrics & Gynecology (journal), Instagram, Use, UI, Adult, SUFU, Cough, LinkedIn, American Urological Association, American College of Obstetricians and Gynecologists, AUA, American College, Obstetrics, Smartphone, Research, Woman, PFMT, Solution, Pelvic floor, Medical Affairs Bureau, Society, Urinary incontinence, Doctor of Pharmacy, All rights reserved, Storey, Engineering, Physician, Overactive bladder, Twitter, Female, ACOG, Sexual dysfunction, Health, Femtech, Quality of life, PDT, FDA, DPT, MUI, FI, Exertion, SUI, Sneeze, Feces, Time, MPH, Urine, Hotel manager, Rehabilitation, Physical, Movement, Mental health, Senior, Patient, PT, Medical device, Medical imaging, Health insurance, Birth control, Gynaecology, Kegel exercise, Gynaecology, Facebook, Urodynamic testing

BOSTON, July 22, 2022 /PRNewswire/ -- Renovia Inc. (Renovia), a developer of non-surgical treatments for female pelvic floor disorders and an advocate for women's health, announced today that Neurourology and Urodynamics published two studies demonstrating low rates of documented adherence to treatment guidelines for female urinary incontinence (UI) care for women and the effect on payer costs. One study showed significantly higher costs for payers in the two years following diagnosis for women whose treatment claims did not align with published guidelines for female UI. A second study showed very low use of physical therapy (PT) for UI, a discipline commonly engaged in first-line care for UI.

Key Points: 
  • BOSTON, July 22, 2022 /PRNewswire/ -- Renovia Inc. (Renovia), a developer of non-surgical treatments for female pelvic floor disorders and an advocate for women's health, announced today that Neurourology and Urodynamics published two studies demonstrating low rates of documented adherence to treatment guidelines for female urinary incontinence (UI) care for women and the effect on payer costs.
  • A second study showed very low use of physical therapy (PT) for UI, a discipline commonly engaged in first-line care for UI.
  • Numerous studies show PFMT isan effective treatment for urinary incontinence and that PFMT, commonly referred to as Kegels, is challenging for women to implement effectively on their own.
  • The study determined that documented care not sequenced in adherence to guidelines increasedpayers' cost burden.